TWIST interacts with β-catenin signaling on osteosarcoma cell survival against cisplatin

Molecular Carcinogenesis

Volumn 53, Issue 6, 2014, Pages 440-446

  Wu, Jianhuang ^a   Liao, Qiande ^a   He, Hongbo ^a   Zhong, Da ^a   Yin, Ke ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cell survival; Cisplatin; Osteosarcoma; TWIST; catenin

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BETA CATENIN; CISPLATIN; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C JUN; SERINE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR TWIST;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL STRAIN MG 63; CELL SURVIVAL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE SILENCING; HUMAN; HUMAN CELL; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SAOS 2 CELL LINE; SIGNAL TRANSDUCTION;

CELL SURVIVAL; CISPLATIN; OSTEOSARCOMA; TWIST; Β-CATENIN;

APOPTOSIS; BETA CATENIN; BONE NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; OSTEOSARCOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TWIST TRANSCRIPTION FACTOR;

EID: 84899928773     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21991     Document Type: Article

References (28)

1. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2010; 152:3-13.
2. Gorlick R, Anderson P, Andrulis I. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: Meeting summary. Clin Cancer Res 2003; 9:5442-5453.
3. Wittig JC, Bickels J, Priebat D. Osteosarcoma: A multidisciplinary approach to diagnosis and treatment. Am Fam Physician 2002; 65:1123-1132.
4. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: Current challenges and future directions. Expert Rev Anticancer Ther 2006; 6:1075-1085.
5. Entz-Werlé N, Lavaux T, Metzger N, et al. Involvement of MET/TWIST/APC combination or the potential role of ossification factors in pediatric high-grade osteosarcoma oncogenesis. Neoplasia 2007; 9:678-688.
6. Stoetzel C, Weber B, Bourgeois P, Bolcato-Bellemin AL, Perrin-Schmitt F. Dorso-ventral and rostro-caudal sequential expression of M-twist in the postimplantation murine embryo. Mech Dev 1995; 51:251-263.
7. El Ghouzzi V, Le Merrer M, Perrin-Schmitt F, et al. Mutations of the TWIST gene in the Saethre-Chotzen syndrome. Nat Genet 1997; 15:42-46.
8. Entz-Werlé N, Choquet P, Neuville A, et al. Targeted apc;twist double-mutant mice: A new model of spontaneous osteosarcoma that mimics the human disease. Transl Oncol 2010; 3:344-353.
9. Le Deley MC, Guinebretière J, Gentet JC, et al. SFOP osteosarcoma94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 2007; 43:752-761.
10. Day TF, Guo X, Garret-Beal L, Yang Y. Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005; 8:739-750.
11. Pinzone JJ, Hall BM, Thudi NK, et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 2009; 113:517-525.
12. Chesire DR, Isaacs WB. β-Catenin signaling in prostate cancer: An early perspective. Endocr Relat Cancer 2003; 10:537-560.
13. Qiang YW, Hu B, Chen Y, et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of β-catenin/TCF signaling. Blood 2009; 113:4319-4330.
14. Nusse R. Repression and activation. Trends Genet 1999; 15:1-3.
15. Stein TJ, Holmes KE, Muthuswamy A, Thompson V, Huelsmeyer MK. Characterization of β-catenin expression in canine osteosarcoma. Vet Comp Oncol 2011; 9:65-73.
16. Matsuo N, Shiraha H, Fujik T, et al. Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer 2009; 9:240.
17. Okamura H, Yoshida K, Haneji T. Negative regulation of TIMP1 is mediated by transcription factor TWIST1. Int J Onc 2009; 35:181-186.
18. Funato N, Ohtani K, Ohyama K, Kuroda T, Nakamura M. Common regulation of growth arrest and differentiation of osteoblasts by Helix-Loop-Helix Factors. Mol Cell Biol 2001; 21:7416-7428.
19. Sharma M, Chuang WW, Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3β inhibition and nuclear β-catenin accumulation. J Biol Chem 2002; 277:30935-30941.
20. Hoang BH, Kudo T, Healey JH, et al. Dickkopf 3 inhibits invasion and motility of saos-2 osteosarcoma cells by modulating the Wnt-β-catenin pathway. Cancer Res 2004; 64:2734-2743.
21. Renard CA, Labalette C, Armengol C, et al. Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer. Cancer Res 2007; 67:901-910.
22. Sasaki K, Hitora T, Yamamoto T, et al. Does the mutation of Wnt occur on osteosarcomas? ESMO 2010 Abstract #2954. http://abstracts.webges.com/viewing/view.php?congress=esmo2010&congress_id=296&publication_id=2954. 2010; Accessed on June 6, 2012.
23. Guenou H, Kaabeche K, Dufour C, Miraoui H, Marie PJ. Down-regulation of ubiquitin ligase Cbl induced by twist haploinsufficiency in Saethre-Chotzen syndrome results in increased PI3K/Akt signaling and osteoblast proliferation. Am J Pathol 2006; 169:1303-1311.
24. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, Korswagen HC. Functional interaction between β-catenin and FOXO in oxidative stress signaling. Science 2005; 308:1181-1184.
25. Sun P, Xiong H, Kim TH, Ren B, Zhang Z. Positive inter-regulation between β-catenin/T cell factor-4 signaling and endothelin-1 signaling potentiates proliferation and survival of prostate cancer cells. Mol Pharmacol 2006; 69:520-531.
26. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 2009; 20:765-776.
27. DiMeo TA, Anderson K, Phadke P, et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 2009; 69:5364-5373.
28. Rosenberg B, Vancamp L, Trosko JE, Mansour VH. Platinum compounds: A new class of potent antitumour agents. Nature 1969; 222:385-386.